361 related articles for article (PubMed ID: 15585832)
1. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
Robbins PF; Dudley ME; Wunderlich J; El-Gamil M; Li YF; Zhou J; Huang J; Powell DJ; Rosenberg SA
J Immunol; 2004 Dec; 173(12):7125-30. PubMed ID: 15585832
[TBL] [Abstract][Full Text] [Related]
2. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
Huang J; Khong HT; Dudley ME; El-Gamil M; Li YF; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(3):258-67. PubMed ID: 15838383
[TBL] [Abstract][Full Text] [Related]
3. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Zhou J; Shen X; Huang J; Hodes RJ; Rosenberg SA; Robbins PF
J Immunol; 2005 Nov; 175(10):7046-52. PubMed ID: 16272366
[TBL] [Abstract][Full Text] [Related]
4. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
5. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunol; 2004 Dec; 173(12):7622-9. PubMed ID: 15585890
[TBL] [Abstract][Full Text] [Related]
6. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
8. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
9. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
Manne J; Mastrangelo MJ; Sato T; Berd D
J Immunol; 2002 Sep; 169(6):3407-12. PubMed ID: 12218163
[TBL] [Abstract][Full Text] [Related]
10. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Rosenberg SA; Yang JC; Robbins PF; Wunderlich JR; Hwu P; Sherry RM; Schwartzentruber DJ; Topalian SL; Restifo NP; Filie A; Chang R; Dudley ME
J Immunother; 2003; 26(5):385-93. PubMed ID: 12973027
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
13. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.
Tahara H; Fujio K; Araki Y; Setoguchi K; Misaki Y; Kitamura T; Yamamoto K
J Immunol; 2003 Aug; 171(4):2154-60. PubMed ID: 12902522
[TBL] [Abstract][Full Text] [Related]
15. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma.
Weidmann E; Elder EM; Trucco M; Lotze MT; Whiteside TL
Int J Cancer; 1993 May; 54(3):383-90. PubMed ID: 8509212
[TBL] [Abstract][Full Text] [Related]
16. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Dudley ME; Wunderlich JR; Robbins PF; Yang JC; Hwu P; Schwartzentruber DJ; Topalian SL; Sherry R; Restifo NP; Hubicki AM; Robinson MR; Raffeld M; Duray P; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; White DE; Rosenberg SA
Science; 2002 Oct; 298(5594):850-4. PubMed ID: 12242449
[TBL] [Abstract][Full Text] [Related]
17. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Rosenberg SA; Dudley ME
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14639-45. PubMed ID: 15381769
[TBL] [Abstract][Full Text] [Related]
18. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
19. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
Huang J; El-Gamil M; Dudley ME; Li YF; Rosenberg SA; Robbins PF
J Immunol; 2004 May; 172(10):6057-64. PubMed ID: 15128789
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
